Abstract A tri-block nanoparticle (TBN) comprising of an enzymatically cleavable porous gelatin nanocore encapsulated with gefitinib (tyrosine kinase inhibitor (TKI)) and surface functionalized with cetuximab-siRNA conjugate has been synthesized. Targeted delivery of siRNA to undruggable KRAS mutated non-small cell lung cancer cells would sensitize the cells to TKI drugs and offers an efficient therapy for […]
As part of our service offering, we are proud to announce successful execution of yet another project with compliance to current Good Manufacturing Practices (cGMP) for supplies for Phase-I clinical study by the client.
Levim has embarked on finding solutions for unmet disease areas in oncology through innovation with its in-house expertise in the area of gene therapy & drug delivery. We have been successful in materializing our concept to a working molecule and see encouraging results in overcoming resistant cancers, that has a potential for wide range of […]
Our biosimilar pipeline has been witnessing constant progress with demonstrated ability to meet important endpoints in various pre-clinical & clinical studies. Please refer to our Product & Technologies page for more information on the products we are working on, updated as & when we are getting closer to the market.
Levim is in advanced stages of development of liraglutide biosimilar and based on the favourable data on analytical characterization of the product, preclinical studies and cost competency, Levim has won this prestigious grant to take the product through clinical development & commercial launch.